CA
CADL.US Candel Therapeutics Inc
- Market cap
- USD 474M
- P/E
- -
- P/B
- 5.10x
- ROE
- -70.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CADL.US undervalued?
Graham numberThe Graham number of Candel Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Candel Therapeutics Inc fundamental analysis
No fundamental analysis for Candel Therapeutics Inc yet.
Candel Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Candel Therapeutics Inc
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Pl…
Full company profileCandel Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Candel Therapeutics Inc annual financial statements
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 125K | 125K | 125K | 125K | 31.0K | 0.00 | 0.00 | - |
| Gross Profit | 125K | 125K | 125K | 125K | -24.0M | -990K | -845K | - |
| Operating Income | -9.04M | -13.8M | -25.7M | -34.7M | -38.4M | -33.4M | -48.3M | -88.0M |
| EBITDA | -8.42M | -13.1M | -35.8M | -16.3M | -34.4M | -52.1M | -35.2M | -89.5M |
| Net Income | -8.24M | -17.7M | -36.1M | -18.8M | -37.9M | -55.2M | -38.2M | -92.9M |
| EPS | -0.44 | -0.94 | -1.91 | -0.65 | -1.31 | -1.74 | -0.72 | -1.20 |
| Balance Sheet | ||||||||
| Total Assets | 45.9M | 38.3M | 89.2M | 78.5M | 41.2M | 107M | 125M | 211M |
| Total Liabilities | 53.9M | 61.8M | 25.1M | 30.8M | 28.5M | 40.5M | 73.3M | 79.5M |
| Shareholders' Equity | -8.04M | -23.6M | 64.1M | 47.7M | 12.7M | 66.3M | 51.9M | 132M |
| Cash & Short-term Investments | 45.1M | 35.1M | 82.6M | 70.1M | 35.4M | 103M | 120M | 203M |
| Total Debt | 420K | 946K | 560K | 22.8M | 22.8M | 13.5M | 1.90M | 1.57M |
| Cash Flow | ||||||||
| Operating Cash Flow | -5.18M | -9.07M | -22.2M | -31.4M | -34.2M | -27.0M | -38.3M | -77.8M |
| Capital Expenditure | 159K | 1.48M | 1.84M | 1.30M | 457K | 16.0K | 587K | 1.18M |
| Free Cash Flow | -5.34M | -10.5M | -24.1M | -32.7M | -34.7M | -27.0M | -38.9M | -79.0M |
| Ratios | ||||||||
| ROE | - | - | -56.3% | -39.4% | -297.7% | -83.2% | -73.5% | -70.6% |
| ROA | -18.0% | -46.2% | -40.5% | -23.9% | -92.1% | -51.6% | -30.5% | -44.0% |
| Net Profit Margin | -6,592.0% | -14,144.0% | -28,899.2% | -15,035.2% | -122,383.9% | - | - | - |
| Debt to Equity | - | - | 0.01x | 0.48x | 1.79x | 0.20x | 0.04x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Candel Therapeutics Inc dividends
Candel Therapeutics Inc has not paid dividends in the last 7 fiscal years.
Who owns Candel Therapeutics Inc
- Insiders 15.50%
- Institutions 67.17%
- Public & others 17.34%
- Shares outstanding 76.5M
- Free float 61.7M
Top funds holding CADL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Select Biotechnology | 4.86M | 6.36% | 0.00% | Aug 2026 |
| State Street® SPDR® S&P® Biotech ETF | 2.34M | 3.06% | +2.69% | Oct 2026 |
| Fidelity Growth Company Fund | 2.29M | 2.99% | +8.67% | Aug 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 2.08M | 2.72% | +5.82% | Sep 2026 |
| Strategic Advisers U.S. Total Stock | 1.91M | 2.50% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 1.61M | 2.11% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 693K | 0.91% | 0.00% | Aug 2026 |
| Fidelity Growth Company K6 | 659K | 0.86% | +9.01% | Aug 2026 |
| Fidelity Series Growth Company | 603K | 0.79% | +8.46% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 550K | 0.72% | -0.38% | Oct 2026 |
| iShares Biotechnology ETF | 472K | 0.62% | -0.19% | Oct 2026 |
| Schwab US Small-Cap ETF™ | 378K | 0.49% | +0.24% | Oct 2026 |
| MEDICAL BioHealth EUR Acc | 371K | 0.48% | -19.92% | Aug 2026 |
| Vanguard Russell 2000 ETF | 369K | 0.48% | +1.15% | Sep 2026 |
| Fidelity Extended Market Index | 324K | 0.42% | +16.05% | Sep 2026 |
| Stt Strt®SPDR®S&PKenshoNwEcosComposETF | 264K | 0.35% | +0.08% | Oct 2026 |
| BANOR SICAV Rosemary S EUR Acc | 222K | 0.29% | -18.34% | Sep 2026 |
| iShares Micro-Cap ETF | 191K | 0.25% | 0.00% | Oct 2026 |
| Schwab Small Cap Index | 153K | 0.20% | -0.21% | Sep 2026 |
| Fidelity Total Market Index | 129K | 0.17% | +6.06% | Sep 2026 |
Top institutions holding CADL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| FMR Inc | 11.0M | 14.36% | +0.03% | Jun 2026 |
| RTW INVESTMENTS, LLC | 6.42M | 8.39% | 0.00% | Jun 2026 |
| BlackRock Inc | 4.97M | 6.49% | +59.83% | Jun 2026 |
| State Street Corp | 3.55M | 4.64% | +333.67% | Jun 2026 |
| Portolan Capital Management, LLC | 3.49M | 4.56% | +20.59% | Jun 2026 |
| Saturn V Capital Management LLC | 3.30M | 4.32% | +14.05% | Jun 2026 |
| Vanguard Capital Management, LLC | 2.69M | 3.52% | +9.39% | Jun 2026 |
| Geode Capital Management, LLC | 1.57M | 2.05% | +51.73% | Jun 2026 |
| Millennium Management LLC | 1.09M | 1.43% | +3.19% | Jun 2026 |
| Northern Trust Corp | 492K | 0.64% | +52.39% | Jun 2026 |
| Kennedy Capital Management Inc | 488K | 0.64% | +427.17% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 437K | 0.57% | +62.96% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 412K | 0.54% | +46.95% | Jun 2026 |
| Sands Capital Ventures, LLC | 406K | 0.53% | 0.00% | Jun 2026 |
| The Goldman Sachs Group Inc | 305K | 0.40% | +34.15% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 301K | 0.39% | 0.00% | Jun 2026 |
| Arete Wealth Advisors, LLC | 290K | 0.38% | 0.00% | Jun 2026 |
| Bank of America Corp | 279K | 0.36% | +488.46% | Jun 2026 |
| Susquehanna International Group, LLP | 228K | 0.30% | +101.76% | Jun 2026 |
| Wellington Management Company LLP | 206K | 0.27% | 0.00% | Jun 2026 |
Candel Therapeutics Inc company profile
- Company name
- Candel Therapeutics Inc
- Ticker
- CADL.US
- Exchange
- USA Stocks
- Listed since
- Jul 27, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 55
- Fiscal year end
- December
- Address
- 117 Kendrick Street, Needham, MA, United States, 02494
- Phone
- 617 916 5445
- Website
- candeltx.com
About Candel Therapeutics Inc
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
Candel Therapeutics Inc management
10- Dr. Paul-Peter Tak FOCIS, M.D., Ph.D.President, CEO & Director · born 1960
- Mr. Charles SchochSenior VP, CFO, Treasurer & Secretary · born 1985
- Dr. Francesca Barone M.D., Ph.D.Chief Scientific Officer · born 1978
- Dr. Seshu Tyagarajan Ph.D.Chief Technical & Development Officer · born 1968
- Mr. Theodore JenkinsVice President of Investor Relations & Business Development
- Ms. Maria OstrovskyGeneral Counsel
- Ms. Ileen B. WinickChief People Officer
- Ms. Susan Stewart J.D., L.L.M.Chief Regulatory Officer · born 1961
- Dr. William Nichols Garrett M.D., M.S.Chief Medical Officer · born 1969
- Mr. Mark SimsChief Commercial Officer